💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tacrolimus Anhydrous

CHEMBL269732 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
804.0 g/mol
LogP
2.7
Phase
4

A anhydrous salt form of tacrolimus with the same therapeutic properties. This medication suppresses the immune system to prevent the body from rejecting a transplanted organ such as a kidney, liver, or heart.

Molekularmasse

804,0000 g/mol

LogP

2,70

TPSA

178,00 Ų

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Cardiovascular Disease Age-Related Macular Degeneration Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Immunology Infectious Disease Melanoma Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Transplant Medicine Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Hepatitis C Prostate Cancer Leukemia

Wirkmechanismus

Calcineurin inhibitor binding FKBP12; suppresses IL-2 transcription.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Calcineurin inhibitor binding FKBP12; suppresses IL-2 transcription.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC

                

                

                
                

                    
InChI

                    
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C44H69NO12

                    

                    
                    

                        
HBD / HBA

                        
3 / 12

                    

                    
                    

                        
Rotierbare Bindungen

                        
7

                    

                    
                    
                    

                        
Schwere Atome

                        
57

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
A anhydrous salt form of tacrolimus with the same therapeutic properties. This medication suppresses the immune system to prevent the body from rejecting a transplanted organ such as a kidney, liver, or heart.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Calcineurin inhibitor binding FKBP12; suppresses IL-2 transcription.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tacrolimus Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL269732.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 445643.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.